Open-label pilot study of quetiapine treatment for cannabis dependence

References

• Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, Publication No. SMA 11-4658; Rockville, MD: Office of Applied Studies, 2011
   Google Scholar
• Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2005;80:105–116
   PubMed Web of Science ®Google Scholar
• Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006;36:1447–1460
   PubMed Web of Science ®Google Scholar
• Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000;68:1051–1061
   PubMed Web of Science ®Google Scholar
• Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 2006;74:307–316
   PubMed Web of Science ®Google Scholar
• Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, Liddle H, et al. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J Subst Abuse Treat 2004;27:197–213
   PubMed Web of Science ®Google Scholar
• Group TMTPR. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004;72:455–466
   Google Scholar
• Kadden RM, Litt MD, Kabela-Cormier E, Petry NM. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007;32:1220–1236
   PubMed Web of Science ®Google Scholar
• Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S, Vosburg SK. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004;13:21–32
   PubMed Web of Science ®Google Scholar
• Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009;18:53–64
   PubMed Web of Science ®Google Scholar
• McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009;105:132–138
   PubMedGoogle Scholar
• Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011;116:142–150
   PubMed Web of Science ®Google Scholar
• Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012;169:805–812
   PubMed Web of Science ®Google Scholar
• Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012;37:1689–1698
   PubMed Web of Science ®Google Scholar
• Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:539–548
   PubMed Web of Science ®Google Scholar
• Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 2008;69:1354–1363
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63:5–11
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876–884
   PubMed Web of Science ®Google Scholar
• Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:1991–2001
   PubMed Web of Science ®Google Scholar
• Twaites BR, Wilton LV, Shakir SA. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. J Psychopharmacol 2007;21:392–399
   Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders- Patient Edition (SCID-I/P, Version 2.0): Biometrics Research Department, New York State Psychiatric Institute, 1995
   Google Scholar
• Litten R, Allen J. Measuring alcohol consumption: psychosocial and biochemical methods. Totowa, NJ: The Humana Press Inc., 1992
   Google Scholar
• Mariani JJ, Brooks D, Haney M, Levin FR. Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug Alcohol Depend 2011;113:249–251
   PubMed Web of Science ®Google Scholar
• Steinberg K, Roffman R, Carroll K, McRee B, Babor T, Miller M, Kadden R, et al. Brief counseling for marijuana dependence. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2005
   Google Scholar
• Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl 2005;15:157–167; discussion 140
   Google Scholar
• Smith PL. Splines as a useful and convenient statistical tool. Am Statistician 1979;33:57–62
   Web of Science ®Google Scholar
• Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161–166
   PubMed Web of Science ®Google Scholar
• Benaliouad F, Kapur S, Rompre PP. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 2007;32:551–561
   Google Scholar
• Gallo A, Lapointe S, Stip E, Potvin S, Rompre PP. Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behav Brain Res 2010;208:163–168
   PubMedGoogle Scholar
• Jasmin L, Narasaiah M, Tien D. Noradrenaline is necessary for the hedonic properties of addictive drugs. Vascular Pharmacol 2006;45:243–250
   Google Scholar
• Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999;94:1311–1322
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 1999;141:385–394
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 2013;18:993–1002
   Google Scholar